Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioCryst Pharmaceuticals, Inc. (BCRX) vs Supernus Pharmaceuticals, Inc. (SUPN)

BioCryst Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Supernus Pharmaceuticals, Inc. is the larger, with a market value of $2.5B against $2.2B — 1.2× the size. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 68.7% against 24.9%. Supernus Pharmaceuticals, Inc. has the higher net margin (−13.2% vs −40.9%) and the higher return on invested capital (−12.4% vs −610.6%). Across the 18 metrics below, BioCryst Pharmaceuticals, Inc. leads on 11 and Supernus Pharmaceuticals, Inc. on 7.

Valuation

Metric BCRX SUPN Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.32 2.98 2.25
P/B n/m 2.40 1.90
Price to free cash flow 5.85 147.92 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 2.84 2.59 2.56
Earnings yield (16.76%) (4.50%) (2.99%)
Free cash flow yield 17.11% 0.68% 0.00%

Profitability

Metric BCRX SUPN Drug Manufacturers Specialty & Generic median
Gross margin 97.78% 88.07% 53.94%
Operating margin (33.29%) (15.71%) 0.00%
Net margin (40.90%) (13.23%) 0.00%
Free cash flow margin 39.75% 2.21% 0.00%
Return on equity 87.84% (10.49%) (0.40%)
Return on assets (75.79%) (7.82%) (3.32%)
Return on invested capital (610.55%) (12.37%) 0.00%

Growth

Metric BCRX SUPN Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 68.72% 24.85% 10.01%
EPS growth (last fiscal year) 381.40% (151.52%) —
Revenue growth, 5-year CAGR 117.89% 6.68% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCRX SUPN Drug Manufacturers Specialty & Generic median
Debt to equity (1.85) 0.00 0.05
Current ratio 2.32 2.08 2.31
Net debt to EBITDA 0.61 (11.12) 0.85

Dividend

Metric BCRX SUPN Drug Manufacturers Specialty & Generic median
Dividend yield 3.71% — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric BCRX SUPN Drug Manufacturers Specialty & Generic median
Market cap 2.18b 2.52b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack